SCHEMBL954374

SCHEMBL954374

Nc1ccc2[nH]nc(C(=O)Nc3ccc(C=S)c(Cl)c3)c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 5/20 0.49
▸ JAK1 P23458 5/20 0.49
▸ CSNK2A1 P68400 5/20 0.47
▸ ULK1 O75385 1/20 0.47
▸ ROCK1 Q13464 1/20 0.45
▸ FLT3 P36888 4/20 0.43
▸ CDK2 P24941 3/20 0.43
▸ CCNA2 P20248 1/20 0.43
▸ CCNA1 P78396 1/20 0.43
▸ MAP4K1 Q92918 1/20 0.42
▸ DYRK1A Q13627 2/20 0.42
▸ WNT1 P04628 1/20 0.42
▸ EPHB3 P54753 1/20 0.42
▸ DYRK3 O43781 1/20 0.41
▸ MAP4K4 O95819 1/20 0.41
▸ CDK1 P06493 1/20 0.41
▸ MARK3 P27448 1/20 0.41
▸ CLK2 P49760 1/20 0.41
▸ GSK3B P49841 1/20 0.41
▸ CSNK1G2 P78368 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4510038 0.91 CSNK2A1 (0.51) JAK2JAK1CSNK2A1ROCK1FLT3
SCHEMBL82695 0.80 CSNK2A1 (0.52) JAK2JAK1CSNK2A1ULK1ROCK1
SCHEMBL28775976 0.77 DYRK1A (0.66) CSNK2A1ULK1ROCK1FLT3CDK2
SCHEMBL4007094 0.76 FLT3 (0.72) JAK2JAK1CSNK2A1ULK1ROCK1
SCHEMBL4531693 0.75 FLT3 (0.55) JAK2JAK1CSNK2A1ULK1FLT3
SCHEMBL952349 0.72 CSNK2A1 (0.69) CSNK2A1FLT3CDK2CCNA2CCNA1
SCHEMBL12193634 0.71 KDM4E (0.53) JAK2JAK1CSNK2A1ULK1FLT3
SCHEMBL2468351 0.70 YTHDC1 (0.65) JAK2JAK1CSNK2A1ULK1FLT3
SCHEMBL14699449 0.70 GSK3B (0.61) DYRK1ACLK2GSK3B
SCHEMBL28776034 0.70 FLT3 (0.56) CSNK2A1ROCK1FLT3DYRK1AMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110021467-A1 INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA SANOFI-AVENTIS (FR) 2011-01-27 — — US disclosed
US-7842711-B2 Indazolecarboxamide derivatives for the treatment and prevention of malaria SANOFI-AVENTIS (FR) 2010-11-30 — — US disclosed
US-20070185187-A1 INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA SANOFI-AVENTIS (FR) 2007-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185187-A1 INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA CYP3A43, CYP3A5, SIRT5 JAK2 3068/4885JAK1 3595/4885CSNK2A1 2594/4885
US-20110021467-A1 INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA CYP3A43, CYP3A5, SIRT5 JAK2 3068/4885JAK1 3595/4885CSNK2A1 2594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback